Short- and Long-term Outcomes of children hospitalized with COVID-19 or Influenza: results of the AUTCOV study
Wagenlechner, C.; Wendt, R.; Reichardt, B.; Mildner, M.; Mascherbauer, J.; Aigner, C.; Auer, J.; Ankersmit, H. J.; Graf, A.
Show abstract
BackgroundRecent literature gives different results on morbidity and mortality after COVID-19 as compared to Influenza hospitalized children and results of large, population based studies are scant. In this population-based study in Austria, we evaluated and compared the short- and long-term outcomes after COVID-19 or Influenza hospitalization and associations with their baseline drug profile. MethodsIndividual data were provided on children [≤] 18 years hospitalized with COVID-19 in the years 2020 and 2021 or Influenza in 2016 - 2021 as well as on age-, sex- and region-matched controls from the Austrian Health Insurance Funds. The primary outcome was time to hospital discharge. Secondary outcomes were in-hospital death, all-cause mortality and readmission to hospital due to any reason. The median follow-up time was 430 days (IQR: 245-552) in the COVID-19 and 1221 days (IQR: 881-1599) in the Influenza group. Results1063 children were hospitalized due to COVID-19 and 2781 children due to Influenza in the study period. Children hospitalized due to COVID-19 or Influenza were more likely to have a larger disease burden as compared to the general population. Influenza hospitalized patients were observed to be generally younger and a larger percentage of polypharmacy than those with COVID-19. No significant difference in the time to hospital discharge was found between cohorts (HR: 1.22 [95%-CI: 0.97-1.55], p=0.093). The risk for readmission was significantly higher for Influenza (HR: 1.23 [95%-CI: 1.03-1.47], p=0.021). In-hospital mortality (0.94% vs. 0.22%, p=0.004) and long-term mortality (p=0.009) was significantly larger in COVID-19 patients. One-year mortality after hospitalization was estimated with 1.13% (CI: 0.49-1.77) in the COVID and 0.32% (CI: 0.11-0.53) in the Influenza group. ConclusionA general picture of COVID-19 being a milder disease compared to Influenza may not be drawn. No significant difference for time to hospital discharge was observed between cohorts but the risk of readmission was significantly larger in the Influenza group. Death rates of COVID-19 hospitalized children seem to be higher, however, the low number of severe events may limit the findings.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 95%
- Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: international observational federated study based on electronic health records through the 4CE consortium 94%
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 94%
Similar papers in this journal
- Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of COVID-19 patients in Japan 94%
- Risk factors for SARS-CoV-2 infection and hospitalisation in children and adolescents in Norway: A nationwide population-based study. 93%
- Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study) 92%
Similar papers in this journal
- Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals 94%
- Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study 94%
- Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults 94%
Similar papers in this journal
- Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study 92%
- Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity 89%
- Effects of cannabidiol on activated immune-inflammatory pathways in major depressive patients and healthy controls 89%
Similar papers in this journal
- Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger than 5 years in Japan, 2011-2022: A database study 93%
- Unveiling the spectrum of Respiratory Syncytial Virus disease in Adults: from Community to Hospital 92%
- Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.